On December 5, 2017, Michael Blume
participated in a panel discussion concerning how recent federal court decisions on legal restrictions for off-label information have applied a heightened degree of First Amendment scrutiny to the government's ability to criminally prosecute off-label promotion. The FDA has been examining its position on off-label and on-label communications as a result of these decisions and as prompted by Congress. This session addressed the quickly shifting status of the law and discussed implications for health law practitioners. Click here
for more information.